CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease

Sheila K. Pierson; Laura Katz; Reece Williams; Melanie Mumau; Michael Gonzalez; Stacy Guzman; Ayelet Rubenstein; Ana B. Oromendia; Philip Beineke; Alexander Fosså; Frits van Rhee; David C. Fajgenbaum

doi:10.1038/s41467-022-34873-7

Nature Communications (Nov 2022)

CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease

Sheila K. Pierson,
Laura Katz,
Reece Williams,
Melanie Mumau,
Michael Gonzalez,
Stacy Guzman,
Ayelet Rubenstein,
Ana B. Oromendia,
Philip Beineke,
Alexander Fosså,
Frits van Rhee,
David C. Fajgenbaum

Affiliations

Sheila K. Pierson: Center for Cytokine Storm Treatment & Laboratory, Department of Medicine, University of Pennsylvania
Laura Katz: Medidata Solutions
Reece Williams: Center for Cytokine Storm Treatment & Laboratory, Department of Medicine, University of Pennsylvania
Melanie Mumau: Center for Cytokine Storm Treatment & Laboratory, Department of Medicine, University of Pennsylvania
Michael Gonzalez: Center for Cytokine Storm Treatment & Laboratory, Department of Medicine, University of Pennsylvania
Stacy Guzman: Center for Cytokine Storm Treatment & Laboratory, Department of Medicine, University of Pennsylvania
Ayelet Rubenstein: Center for Cytokine Storm Treatment & Laboratory, Department of Medicine, University of Pennsylvania
Ana B. Oromendia: Medidata Solutions
Philip Beineke: Medidata Solutions
Alexander Fosså: Department of Oncology, Oslo University Hospital
Frits van Rhee: Myeloma Center, University of Arkansas for Medical Sciences
David C. Fajgenbaum: Center for Cytokine Storm Treatment & Laboratory, Department of Medicine, University of Pennsylvania

DOI: https://doi.org/10.1038/s41467-022-34873-7
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 13

Abstract

Read online

Idiopathic multicentric Castleman disease (iMCD) is a life-threatening inflammatory disease requiring immediate intervention, for which the recommended first-line therapy is the Interleukin-6 pathway inhibitor siltuximab. Authors here show that the change in levels of the chemokine CXCL13 shortly following the start of siltuximab treatment is predictive of response.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal